🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521394-13-00
Authorised Phase I

A Phase 1 Study of AUTX-703 in Participants with Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndromes

2025-521394-13-00 · tracked via the Priya Life Science EU tracker
Sponsor
Auron Therapeutics Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
04/02/2026
Enrollment target
10
Sites
France

Condition studied

Relapsed/refractory Acute Myeloid Leukemia or relapsed/refractory myelodysplastic syndromes

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521394-13-00 on CTIS ↗ ← All trials in the EU